A study to compare the effectiveness of combination of drugs to be given in keloid. The participants will either be given The drug combination Triamcinolone acetonide and CO2 laser or Triamcinolone acetonide and Hyaluronidase. The main outcome will be decreased size, symptoms of pain and itching.

A Comparative Study Evaluating Efficacy Of Combination Therapy Of Intralesional Triamcinolone Acetonide With Fractional CO2 Laser Versus Intralesional Triamcinolone Acetonide With Hyaluronidase In Management Of Keloids - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106811

Enrollment

120

Registered

2026-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L918- Other hypertrophic disorders of the skin

Interventions

Intervention1: Nil: Nil Intervention2: Triamcinolone acetonide combined with fractional CO2 laser.: Patient treated with fractional CO2 laser followed by intralesional triamcinolone acetonide. Fractio

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 18 to 60 years Patients with clinically diagnosed keloid No prior treatment within the last six months Willingness to participate and provide informed consent

Exclusion criteria

Exclusion criteria: Active infection at the lesion site 2. Known hypersensitivity to corticosteroids 3. Immunocompromised individuals or patients on immuno suppressive therapy 4. Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Assessing the degree of reduction in keloid size in both treatment groups. Evaluating the improvement in symptoms like pain and itching. Determining recurrence rates post treatment Analysing any adverse effect associated with either treatment approach Timepoint: First assessment will be done for half an hour after completion of treatment procedure Next follow up at three months Last follow up at six months	—

Measure

Time frame

Assessing the degree of reduction in keloid size in both treatment groups. Evaluating the improvement in symptoms like pain and itching. Determining recurrence rates post treatment Analysing any adverse effect associated with either treatment approach Timepoint: First assessment will be done for half an hour after completion of treatment procedure Next follow up at three months Last follow up at six months

—

Secondary

Measure	Time frame
NILTimepoint:	—

Countries

India

Contacts

Public ContactPranjal Palan

Parul institute of medical sciences and research

somlakhani24@gmail.com9825350198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026